Discovery Programs

Iksuda is building an extensive early-stage ProAlk-ADC pipeline.

With clinical validation of the glucuronide-driven payload activation approach toward enhanced ADC profiles, Iksuda is now focused on advancing a new wave of ADCs which utilizes its new payload class, with targets that are both known and novel to the ADC field. 

ProAlk has high cytotoxic potency across a full range of cancers with IC50s in the fM to pM range. Allayed to this, its unprecedented level of bystander activity opens the door to treat solid tumors with heterogeneous/ low expression, and its lack of MDR-resistance allows selection of chemo-resistant tumors.  

Iksuda is currently assessing tumor subtypes and targets for heightened ProAlk sensitivity, with a focus on cancers of the lung, colon, GI tract, esophagus, head & neck, bladder, kidney and breast. Our target selection is largely based on a relevance in multiple tumors. We are also developing biomarkers of ProAlk sensitivity to further inform to our choices.  

Our targets include both known (in the ADC field) and novel antigens, where we work with leading collaborators who are highly skilled and knowledgeable in the relevant field.

All ProAlk-ADCs will contain tumor-selective payload activation & release for added safety, and PermaLink bioconjugation for ADC stability.